irsogladine has been researched along with bucladesine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirata, Y; Kimura, K; Kyoi, T; Ueda, F; Watanabe, M | 1 |
| Kyoi, T; Noda, K; Oka, M; Ukai, Y | 1 |
2 other study(ies) available for irsogladine and bucladesine
| Article | Year |
|---|---|
Changes in cyclic AMP content of rat gastric mucosa induced by ulcerogenic stimuli--in relation to the antiulcer activity of irsogladine maleate.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Bucladesine; Cyclic AMP; Gastric Acid; Gastric Mucosa; Male; Pylorus; Rats; Rats, Inbred Strains; Stomach Ulcer; Triazines | 1991 |
Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Anti-Ulcer Agents; Bucladesine; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Gastric Mucosa; Humans; Isoenzymes; Isoquinolines; Neutrophils; Rolipram; Sulfonamides; Superoxides; Triazines | 2004 |